{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T14:02:30Z","timestamp":1792245750104,"version":"4.4.0"},"reference-count":34,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,8]]},"abstract":"<jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>Mucormycosis is a rare but emerging life-threatening fungal disease with limited treatment options. Isavuconazole is a new triazole that has shown efficacy in adults for primary and salvage treatment of mucormycosis. However, data in children are scarce.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>The demographic and clinical data of pediatric patients with proven mucormycosis who were treated with isavuconazole in 2015 to 2019 at 2 centers were collected.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>Four children of median age 10.5 years (range 7\u201314) met the study criteria. Three had underlying hematologic malignancies, and 1 had sustained major trauma. Isavuconazole was used as salvage therapy in all: in 3 patients for refractory disease, and in 1 after intolerance to another antifungal drug. Isavuconazole was administered alone or combined with other antifungal agents. Following treatment and surgical intervention, complete clinical, radiologic and mycologic responses were documented in all patients. A literature review identified 8 children with mucormycosis who were successfully treated with isavuconazole, as salvage therapy in the majority.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion:<\/jats:title>\n            <jats:p>Our limited experience supports the use of isavuconazole as salvage therapy in pediatric mucormycosis.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/inf.0000000000002671","type":"journal-article","created":{"date-parts":[[2020,4,6]],"date-time":"2020-04-06T18:44:02Z","timestamp":1586198642000},"page":"718-724","source":"Crossref","is-referenced-by-count":38,"title":["Isavuconazole As Successful Salvage Therapy for Mucormycosis in Pediatric Patients"],"prefix":"10.1097","volume":"39","author":[{"given":"Liat","family":"Ashkenazi-Hoffnung","sequence":"first","affiliation":[{"name":"Day Hospitalization Department, Infectious Diseases Unit, Hemato-Oncology Department, Intensive Care Unit, Schneider Children\u2019s Medical Center of Israel, Petah Tikva"},{"name":"Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Efraim","family":"Bilavsky","sequence":"additional","affiliation":[{"name":"Day Hospitalization Department, Infectious Diseases Unit, Hemato-Oncology Department, Intensive Care Unit, Schneider Children\u2019s Medical Center of Israel, Petah Tikva"},{"name":"Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Itzhak","family":"Levy","sequence":"additional","affiliation":[{"name":"Day Hospitalization Department, Infectious Diseases Unit, Hemato-Oncology Department, Intensive Care Unit, Schneider Children\u2019s Medical Center of Israel, Petah Tikva"},{"name":"Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Galia","family":"Grisaru","sequence":"additional","affiliation":[{"name":"Day Hospitalization Department, Infectious Diseases Unit, Hemato-Oncology Department, Intensive Care Unit, Schneider Children\u2019s Medical Center of Israel, Petah Tikva"},{"name":"Infectious Diseases Unit & Intensive Care Unit, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Efraim","family":"Sadot","sequence":"additional","affiliation":[{"name":"Day Hospitalization Department, Infectious Diseases Unit, Hemato-Oncology Department, Intensive Care Unit, Schneider Children\u2019s Medical Center of Israel, Petah Tikva"},{"name":"Infectious Diseases Unit & Intensive Care Unit, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronen","family":"Ben-Ami","sequence":"additional","affiliation":[{"name":"Day Hospitalization Department, Infectious Diseases Unit, Hemato-Oncology Department, Intensive Care Unit, Schneider Children\u2019s Medical Center of Israel, Petah Tikva"},{"name":"Infectious Diseases Unit & Intensive Care Unit, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Novikov","sequence":"additional","affiliation":[{"name":"Infectious Diseases Unit & Intensive Care Unit, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salvador","family":"Fischer","sequence":"additional","affiliation":[{"name":"Day Hospitalization Department, Infectious Diseases Unit, Hemato-Oncology Department, Intensive Care Unit, Schneider Children\u2019s Medical Center of Israel, Petah Tikva"},{"name":"Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elhanan","family":"Nahum","sequence":"additional","affiliation":[{"name":"Day Hospitalization Department, Infectious Diseases Unit, Hemato-Oncology Department, Intensive Care Unit, Schneider Children\u2019s Medical Center of Israel, Petah Tikva"},{"name":"Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oded","family":"Scheuerman","sequence":"additional","affiliation":[{"name":"Day Hospitalization Department, Infectious Diseases Unit, Hemato-Oncology Department, Intensive Care Unit, Schneider Children\u2019s Medical Center of Israel, Petah Tikva"},{"name":"Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2020,3,30]]},"reference":[{"key":"R1-20230912","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1086\/432579","article-title":"Epidemiology and outcome of zygomycosis: a review of 929 reported cases.","volume":"41","author":"Roden","year":"2005","journal-title":"Clin Infect Dis"},{"key":"R2-20230912","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1111\/j.1469-0691.2010.03456.x","article-title":"Zygomycosis in Europe: analysis of 230 cases accrued by the registry of the European Confederation of Medical Mycology (ECMM) Working Group on Zygomycosis between 2005 and 2007.","volume":"17","author":"Skiada","year":"2011","journal-title":"Clin Microbiol Infect"},{"key":"R3-20230912","doi-asserted-by":"crossref","first-page":"e0179136","DOI":"10.1371\/journal.pone.0179136","article-title":"Increasing incidence of mucormycosis in a large Spanish hospital from 2007 to 2015: epidemiology and microbiological characterization of the isolates.","volume":"12","author":"Guinea","year":"2017","journal-title":"PLoS One"},{"key":"R4-20230912","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1111\/myc.12222","article-title":"Stability in the cumulative incidence, severity and mortality of 101 cases of invasive mucormycosis in high-risk patients from 1995 to 2011: a comparison of eras immediately before and after the availability of voriconazole and echinocandin-amphotericin combination therapies.","volume":"57","author":"Abidi","year":"2014","journal-title":"Mycoses"},{"key":"R5-20230912","doi-asserted-by":"crossref","first-page":"e785","DOI":"10.1111\/j.1439-0507.2011.02025.x","article-title":"Mucormycosis in paediatric patients: demographics, risk factors and outcome of 12 contemporary cases.","volume":"54","author":"D\u00e4britz","year":"2011","journal-title":"Mycoses"},{"key":"R6-20230912","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1186\/1824-7288-39-77","article-title":"Rhinocerebral zygomycosis with pansinusitis in a 14-year-old girl with type 1 diabetes: a case report and review of the literature.","volume":"39","author":"di Coste","year":"2013","journal-title":"Ital J Pediatr"},{"key":"R7-20230912","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1186\/s12879-016-2005-1","article-title":"Invasive mucormycosis in children: an epidemiologic study in European and non-European countries based on two registries.","volume":"16","author":"Pana","year":"2016","journal-title":"BMC Infect Dis"},{"key":"R8-20230912","doi-asserted-by":"crossref","first-page":"ofw268","DOI":"10.1093\/ofid\/ofw268","article-title":"Trends in hospitalizations related to invasive aspergillosis and mucormycosis in the United States, 2000\u20132013.","volume":"4","author":"Vallabhaneni","year":"2017","journal-title":"Open Forum Infect Dis"},{"key":"R9-20230912","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.3201\/eid2007.140087","article-title":"Population-based analysis of invasive fungal infections, France, 2001\u20132010.","volume":"20","author":"Bitar","year":"2014","journal-title":"Emerg Infect Dis"},{"key":"R10-20230912","doi-asserted-by":"crossref","first-page":"e405","DOI":"10.1016\/S1473-3099(19)30312-3","article-title":"Global guideline for the diagnosis and management of mucormycosis: an initiative of the European Confederation of Medical Mycology in cooperation with the Mycoses Study Group Education and Research Consortium.","volume":"19","author":"Cornely","year":"2019","journal-title":"Lancet Infect Dis"},{"key":"R11-20230912","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1007\/s11046-010-9324-3","article-title":"Isavuconazole: a comprehensive review of spectrum of activity of a new triazole.","volume":"170","author":"Thompson","year":"2010","journal-title":"Mycopathologia"},{"key":"R12-20230912","doi-asserted-by":"crossref","first-page":"7735","DOI":"10.1128\/AAC.01919-15","article-title":"In vitro activity of isavuconazole and comparators against clinical isolates of the mucorales order.","volume":"59","author":"Arendrup","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"R13-20230912","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1016\/S1473-3099(16)00071-2","article-title":"Isavuconazole treatment for mucormycosis: a single-arm open-label trial and case-control analysis.","volume":"16","author":"Marty","year":"2016","journal-title":"Lancet Infect Dis"},{"key":"R14-20230912","article-title":"Revision and update of the consensus definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium.","author":"Donnelly","year":"2019","journal-title":"Clin Infect Dis"},{"key":"R16-20230912","doi-asserted-by":"crossref","first-page":"e27281","DOI":"10.1002\/pbc.27281","article-title":"Successful treatment of invasive mucormycosis with isavuconazole in pediatric patients.","volume":"65","author":"Barg","year":"2018","journal-title":"Pediatr Blood Cancer"},{"key":"R17-20230912","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1007\/s11046-018-0287-0","article-title":"Isavuconazole in a successful combination treatment of disseminated mucormycosis in a child with acute lymphoblastic leukaemia and generalized haemochromatosis: a case report and review of the literature.","volume":"184","author":"Pomorska","year":"2019","journal-title":"Mycopathologia"},{"key":"R18-20230912","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1186\/s40360-018-0273-7","article-title":"Successful outcome of disseminated mucormycosis in a 3-year-old child suffering from acute leukaemia: the role of isavuconazole? A case report.","volume":"19","author":"Cornu","year":"2018","journal-title":"BMC Pharmacol Toxicol"},{"issue":"s1","key":"R19-20230912","first-page":"S7","article-title":"Novel management of invasive Rhizopus fungal sinusitis in a pediatric patient with severe aplastic anemia. PBMTC Poster #5010.","volume":"63","author":"Taylor","year":"2016","journal-title":"Pediatr Blood Cancer"},{"key":"R20-20230912","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1111\/myc.12862","article-title":"Invasive mucormycosis in children with cancer: a retrospective study from the Infection Working Group of Italian Pediatric Hematology Oncology Association.","volume":"62","author":"Muggeo","year":"2019","journal-title":"Mycoses"},{"key":"R22-20230912","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1128\/JCM.00318-16","article-title":"Role of antifungal susceptibility testing in non-Aspergillus invasive mold infections.","volume":"54","author":"Lamoth","year":"2016","journal-title":"J Clin Microbiol"},{"key":"R23-20230912","doi-asserted-by":"crossref","first-page":"2310","DOI":"10.1128\/AAC.46.7.2310-2312.2002","article-title":"In vivo activity of posaconazole against Mucor spp. in an immunosuppressed-mouse model.","volume":"46","author":"Sun","year":"2002","journal-title":"Antimicrob Agents Chemother"},{"key":"R24-20230912","doi-asserted-by":"crossref","first-page":"3647","DOI":"10.1128\/AAC.47.11.3647-3650.2003","article-title":"Activity of posaconazole in treatment of experimental disseminated zygomycosis.","volume":"47","author":"Dannaoui","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"key":"R25-20230912","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1093\/jpids\/piu074","article-title":"A prospective, international cohort study of invasive mold infections in children.","volume":"4","author":"Wattier","year":"2015","journal-title":"J Pediatric Infect Dis Soc"},{"issue":"suppl 3","key":"R26-20230912","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1111\/myc.12247","article-title":"Mucormycosis in haematological patients: case report and results of prospective study in Saint Petersburg, Russia.","volume":"57","author":"Klimko","year":"2014","journal-title":"Mycoses"},{"key":"R27-20230912","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1086\/589857","article-title":"Combination polyene-caspofungin treatment of rhino-orbital-cerebral mucormycosis.","volume":"47","author":"Reed","year":"2008","journal-title":"Clin Infect Dis"},{"key":"R28-20230912","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1016\/j.ijantimicag.2018.08.005","article-title":"Rare mould infections caused by Mucorales, Lomentospora prolificans and Fusarium, in San Diego, CA: the role of antifungal combination therapy.","volume":"52","author":"Jenks","year":"2018","journal-title":"Int J Antimicrob Agents"},{"key":"R29-20230912","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1016\/S0140-6736(15)01159-9","article-title":"Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial.","volume":"387","author":"Maertens","year":"2016","journal-title":"Lancet"},{"key":"R30-20230912","article-title":"Isavuconazole treatment of cerebral and pulmonary aspergillosis in a pediatric patient with acute lymphoblastic leukemia: case report and review of literature.","author":"De Leonardis","year":"2019","journal-title":"J Pediatr Hematol Oncol"},{"key":"R32-20230912","doi-asserted-by":"crossref","first-page":"e01034","DOI":"10.1128\/AAC.01034-17","article-title":"Exposure-response relationships for isavuconazole in patients with invasive aspergillosis and other filamentous fungi.","volume":"61","author":"Desai","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"R33-20230912","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1159\/000494329","article-title":"Isavuconazole: case report and pharmacokinetic considerations.","volume":"63","author":"Marchesi","year":"2018","journal-title":"Chemotherapy"},{"issue":"suppl_1","key":"R34-20230912","doi-asserted-by":"crossref","first-page":"i12","DOI":"10.1093\/jac\/dkx029","article-title":"Therapeutic drug monitoring for invasive mould infections and disease: pharmacokinetic and pharmacodynamic considerations.","volume":"72","author":"Stott","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"R35-20230912","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1097\/INF.0000000000002418","article-title":"Isavuconazole-induced acute liver failure in a pediatric patient with invasive aspergillosis.","volume":"38","author":"Brivio","year":"2019","journal-title":"Pediatr Infect Dis J"},{"key":"R36-20230912","doi-asserted-by":"crossref","first-page":"433","DOI":"10.3324\/haematol.2016.152900","article-title":"ECIL-6 guidelines for the treatment of invasive candidiasis, aspergillosis and mucormycosis in leukemia and hematopoietic stem cell transplant patients.","volume":"102","author":"Tissot","year":"2017","journal-title":"Haematologica"},{"key":"R37-20230912","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1007\/s00520-016-3412-y","article-title":"Critical review of current clinical practice guidelines for antifungal therapy in paediatric haematology and oncology.","volume":"25","author":"Morgan","year":"2017","journal-title":"Support Care Cancer"}],"container-title":["Pediatric Infectious Disease Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/INF.0000000000002671","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,12]],"date-time":"2023-09-12T23:10:49Z","timestamp":1694560249000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/INF.0000000000002671"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3,30]]},"references-count":34,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.1097\/inf.0000000000002671","relation":{},"ISSN":["0891-3668"],"issn-type":[{"value":"0891-3668","type":"print"}],"subject":[],"published":{"date-parts":[[2020,3,30]]}}}